| Name | Dobutamine hydrochloride |
| Description | Dobutamine hydrochloride (Dobutamine (hydrochloride)) is a catecholamine that acts as a β-adrenergic receptor agonist with potent positive inotropic effects. |
| Animal Research | Animal Model:Tgαq*44 mice (heart failure models). Dosage:0.15 mg/kg, 0.5 mg/kg as a low dose, 1.5 mg/kg, 5 mg/kg, 20 mg/kg as a high dose. Administration:Intraperitoneal injection |
| In vivo | In wildtype mice increasing doses of dobutamine resulted in subsequent increase in the left ventricular function and heart rate acceleration, but significant inotropic, lusitropic, and chronotropic cardiac response was observed only after high doses of dobutamine. |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 20 mg/mL (59.2 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.92 mM), Sonication is recommended. DMSO : 65 mg/mL (192.4 mM), Sonication is recommended.
|
| Keywords | sympathomimetic | shock | Inhibitor | inhibit | heart failure | drug | Dobutamine hydrochloride | Dobutamine | cardiogenic | Beta Receptor | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Trifluoperazine dihydrochloride | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Isoprenaline hydrochloride | D-Mannitol | Mianserin hydrochloride | Trazodone hydrochloride | Atenolol | Doxepin hydrochloride |
| Related Compound Libraries | Polyphenolic Natural Product Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |